Successful use of transarterial radioembolization with yttrium‐90 (TARE‐Y90) in two children with hepatoblastoma

Aguado, Allison; Dunn, Stephen P.; Averill, Lauren W.; Chikwava, Kudakwashe R.; Gresh, Renee; Rabinowitz, Deborah; Katzenstein, Howard M.

doi:10.1002/pbc.28421

Cited by 21 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transarterial chemo- or radio-embolisation: TACE or TARE is occasionally used to increase resectability in children who are not resectable and are not liver transplant candidates due to uncontrolled metastatic disease [ 12 , 13 ]. It has also been used to maintain tumour control for patients who have completed protocol systemic chemotherapy but for whom a donor organ for a needed transplant is not yet available.…”

Section: Other Surgical Considerationsmentioning

confidence: 99%

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines

Abib¹,

Chui²,

Cox³

et al. 2022

ecancer

View full text Add to dashboard Cite

Most children with tumors will require one or more surgical interventions as part of the care and treatment, including making a diagnosis, obtaining adequate venous access, performing a surgical resection for solid tumors (with staging and reconstruction), performing procedures for cancer prevention and its late effects, and managing complications of treatment; all with the goal of improving survival and quality of life. It is important for surgeons to adhere to sound pediatric surgical oncology principles, as they are closely associated with improved local control and survival. Unfortunately, there is a significant disparity in survival rates in low and middle income countries, when compared to those from high income countries.The International Society of Paediatric Surgical Oncology (IPSO) is the leading organization that deals with pediatric surgical oncology worldwide. This organization allows experts in the field from around the globe to gather and address the surgical needs of children with cancer. IPSO has been invited to contribute surgical guidance as part of the World Health Organization Initiative for Childhood Cancer. One of our goals is to provide surgical guidance for different scenarios, including those experienced in High-(HICs) and Low-and Middle-Income Countries (LMICs). With this in mind, the following guidelines have been developed by authors from both HICs and LMICs. These have been further validated by experts with the aim of providing evidence-based information for surgeons who care for children with cancer.We hope that this initiative will benefit children worldwide in the best way possible.

show abstract

Section: Other Surgical Considerationsmentioning

confidence: 99%

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines

Abib¹,

Chui²,

Cox³

et al. 2022

ecancer

View full text Add to dashboard Cite

show abstract

“…Most of these studies focus on TACE or TABE, reporting modest rates of tumor response and improved survival [ 32 , 33 , 34 , 35 ]. The only data available for TARE in hepatic sarcomas come from one multi-institutional retrospective study and case reports [ 19 , 36 , 37 ]. However, TARE is particularly appealing due to the lower incidence of post-embolization syndrome and hospital stays of only 2–3 h compared to TACE and other LDTs that often require hospitalization for 1–3 days [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas

Testa

Bui

Wang

et al. 2022

Cancers

View full text Add to dashboard Cite

Patients with liver-dominant metastatic or primary hepatic soft tissue sarcomas (STS) have poor prognosis. Surgery can prolong survival, but most patients are not surgical candidates, and treatment response is limited with systemic chemotherapy. Liver-directed therapies have been increasingly employed in this setting, and Yttrium-90 trans-arterial radioembolization (TARE) is an understudied yet promising treatment option. This is a retrospective analysis of 35 patients with metastatic or primary hepatic STS who underwent TARE at a single institution between 2006 and 2020. The primary outcomes that were measured were overall survival (OS), liver progression-free survival (LPFS), and radiologic tumor response. Clinical and biochemical toxicities were assessed 3 months after the procedure. Median OS was 20 months (95% CI: 13.9–26.1 months), while median LPFS was 9 months (95% CI: 6.2–11.8 months). The objective response rate was 56.7%, and the disease control rate was 80.0% by mRECIST at 3 months. The following correlated with better OS post-TARE: liver disease control (DC) at 6 months (median OS: 40 vs. 17 months, p = 0.007); LPFS ≥ 9 months (median OS: 50 vs. 8 months, p < 0.0001); ECOG status 0–1 vs. 2 (median OS: 22 vs. 6 months, p = 0.042); CTP class A vs. B (median OS: 22 vs. 6 months, p = 0.018); and TACE post-progression (median OS: 99 vs. 16 months, p = 0.003). The absence of metastases at diagnosis was correlated with higher median LPFS (7 vs. 1 months, p = 0.036). Two grade 4 (5.7%) and ten grade 3 (28.6%) laboratory toxicities were identified at 3 months. There was one case of radioembolization-induced liver disease and two cases of radiation-induced peptic ulcer disease. We concluded that TARE could be an effective and safe treatment option for patients with metastatic or primary hepatic STS with good tumor response rates, low incidence of severe toxicity, and longer survival in patients with liver disease control post-TARE.

show abstract

“…These techniques are already used as bridge therapy for adult patients and, though still not widespread for pediatric ones, should be considered. A retrospective study showed no differences in safety and in the response rate to RA in relapsed HB compared with surgery, as well as an alternative to tumors that did not respond to neoadjuvant therapy [18][19][20][21][22] .…”

Section: Rev Col Bras Cir 49:e20223273mentioning

confidence: 99%

Primary Malignant Liver Tumors: eight-year experience in a Pediatric Hospital in Brazil. A cross-sectional study

Falqueto¹,

Vilar²,

Campos³

et al. 2022

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

Introduction: liver tumors are rare neoplasms in childhood (1-2%), and about 2/3 are malignant. Hepatoblastoma (HB) is the most frequent, followed by hepatocellular carcinoma (HCC). In both, the main treatment is surgical resection. Currently, chemotherapy and liver transplantation have improved outcomes. Objective: study of the epidemiological profile and evolution of liver cancer cases in a referral pediatric hospital. Methodology: a retrospective survey of medical records of patients aged up to 18 years with a diagnosis of primary malignant hepatic neoplasm between 2012 and 2020, carried out in the largest exclusively pediatric hospital in Brazil. Results: a total of 13 patients with malignant liver tumors (HB 12, HCC 1) were treated. Of the HB cases, 66,7% were male, with a mean age of 2 years and the main alteration in the palpable abdominal mass. Tumors involved an average of 3 liver segments, more in the right lobe (54%). Only one patient was treated with surgery without neoadjuvant therapy, another one underwent transplantation like the first treatment, and another 2 required liver transplantation as a rescue. The middle follow-up time of patients with HB was 39 months and only 1 case died due to febrile neutropenia. The 5-year overall and disease-free survival was 91.7% and 81.5%, respectively. Conclusion: Advanced staging at the time of diagnosis has always been a poor prognostic factor in patients with primary malignant liver tumors. However, the results and survival have improved with the advancement of chemotherapy, surgical technique, and liver transplantation.

show abstract

Successful use of transarterial radioembolization with yttrium‐90 (TARE‐Y90) in two children with hepatoblastoma

Cited by 21 publications

References 25 publications

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines

Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas

Primary Malignant Liver Tumors: eight-year experience in a Pediatric Hospital in Brazil. A cross-sectional study

Contact Info

Product

Resources

About